Cancer Target Collaboration Agreement Signed Between MedImmune and Georgetown University
MedImmune, Inc. announced that it has entered into a licensing and collaboration agreement with Georgetown University for the development of monoclonal antibodies (MAbs) targeting anaplastic lymphoma kinase (ALK), a member of the insulin receptor family of tyrosine kinases. ALK is believed to play an important role in the growth of solid tumors including those associated with prostate, colon and lung cancers.
Under the terms of the agreement, MedImmune will receive exclusive worldwide rights to develop oncology therapies using MAbs targeting ALK. MedImmune will be responsible for the clinical development and commercialization of any resulting products. Georgetown University will receive an upfront payment as well as potential development milestone payments and royalties on future marketed products. The organizations will also participate in an ongoing research collaboration as part of the agreement.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Artificial intelligence could improve therapy for lymphoma
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Yale Researchers Discover New Potential Asthma Therapeutic Targets Related to Parasites and Insects
Protagen Expands Cooperation with Bayer HealthCare
Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Bayer: Supervisory Board extends CEO Werner Baumann’s - Contract until the end of April 2024

Restoring vision by gene therapy - Latest scientific findings give hope for people with incurable retinal degeneration
Pantec Biosolutions receives ISO 13485 certification
Stora Enso awarded as Finland’s most startup-friendly company
Genetic screening before embryo transfer fails to improve the chance of a baby
